Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency

• Published in: Journal of Clinical Microbiology Vol. 44; no. 7; pp. 2612 - 2614
• Main Authors: Halvas, Elias K, Aldrovandi, Grace M, Balfe, Peter, Beck, Ingrid A, Boltz, Valerie F, Coffin, John M, Frenkel, Lisa M, Hazelwood, J. Darren, Johnson, Victoria A, Kearney, Mary, Kovacs, Andrea, Kuritzkes, Daniel R, Metzner, Karin J, Nissley, Dwight V, Nowicki, Marek, Palmer, Sarah, Ziermann, Rainer, Zhao, Richard Y, Jennings, Cheryl L, Bremer, James, Brambilla, Don, Mellors, John W
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.07.2006
• Subjects: Anti-HIV Agents - pharmacology; Drug Resistance, Viral - genetics; HIV Reverse Transcriptase - genetics; HIV-1 - drug effects; HIV-1 - genetics; HIV-1 - isolation & purification; Human immunodeficiency virus 1; Humans; Molecular Diagnostic Techniques; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Virology; Virology - methods
• ISSN: 0095-1137; 1098-660X; 1098-5530
• DOI: 10.1128/JCM.00449-06

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.